LYFE Sciences · Project HERA
Variant Interpretation · Classification Report
Variant classification summary
NM_000314.8:c.786del
PTEN
· NP_000305.3:p.(Asn262LysfsTer4)
· NM_000314.8
GRCh37: chr10:89717760 AC>A
·
GRCh38: chr10:87958003 AC>A
Gene:
PTEN
Transcript:
NM_000314.8
Final call
Likely Pathogenic
PVS1 very strong
PM2 supporting
Variant details
Gene
PTEN
Transcript
NM_000314.8
Protein
NP_000305.3:p.(Asn262LysfsTer4)
gnomAD AF
ClinVar
OncoKB
Likely Oncogenic
Classification rationale
Interpretation summary
Generated evidence synthesis
1
Pathogenic evidence: PVS1 very strong because the exon 7 frameshift introduces a premature stop before the PTEN NMD threshold.
2
Pathogenic evidence: PM2 supporting because the variant is absent from gnomAD v2.1 and v4.1.
3
Likely Pathogenic: PVS1 very strong plus PM2 supporting satisfy the PTEN Expert Panel's Rule20.
Final determination:
Under Rule20 of the ClinGen PTEN Expert Panel Version 3.2 framework, one Pathogenic.Very Strong criterion plus one Pathogenic.Supporting criterion yields Likely Pathogenic.
Criteria assessment
ACMG/AMP criteria review
Criteria shown when status is available
All criteria require review: For research and educational purposes only.
| Criterion | Status | Rationale | Evidence used |
|---|---|---|---|
| PVS1 | Met | Met at very strong strength: the exon 7 frameshift creates a premature stop at codon 265, 5' of the p.D375 NMD threshold in NM_000314.8. |
cspec
vcep_pvs1_decisiontree_pten
pvs1_variant_assessment
|
| PS1 | N/A | Not applicable: c.786del is a frameshift, whereas PS1 requires the same amino-acid change or a specified pathogenic splicing comparison. |
cspec
pvs1_variant_assessment
|
| PS2 | Not assessed | Not assessed: no proband-level parental testing, de novo observation, disease status, or family-history evidence is available. |
cspec
|
| PS3 | Not assessed | Not assessed: this frameshift has no c.786del, p.Asn262LysfsTer4, or p.N262Kfs*4 assay row in the governing mmc2.xlsx dataset. |
cspec
vcep_mmc2
PMID:29706350
|
| PS4 | Not assessed | Not assessed: no variant-carrier case/control counts, odds ratio, or VCEP phenotype-specificity scores are available to evaluate PS4. |
cspec
gnomad_v2
gnomad_v4
gnomad_canada
|
| PM1 | Not met | Not met: the frameshift begins at residue 262, outside all VCEP-approved PM1 catalytic motifs (90-94, 123-130, and 166-168). |
cspec
pvs1_variant_assessment
hotspots
|
| PM2 | Met | Met at Supporting: the variant is absent from gnomAD v2.1 and v4.1, consistent with the VCEP requirement of <0.00001 (0.001%) allele frequency. |
cspec
gnomad_v2
gnomad_v4
|
| PM3 | N/A | Not applicable: the PTEN VCEP explicitly states that PM3 is not applicable to PTEN. |
cspec
|
| PM4 | N/A | Not applicable: the variant is a frameshift with a premature stop, whereas PTEN PM4 is limited to in-frame length changes and stop-loss extensions. |
cspec
pvs1_variant_assessment
|
| PM5 | N/A | Not applicable: c.786del is a frameshift, but PM5 requires a missense change at a residue with a different pathogenic or likely pathogenic missense change. |
cspec
pvs1_variant_assessment
|
| PM6 | Not assessed | Not assessed: no presumed de novo observations, parental-testing results, proband disease status, or family-history evidence is available. |
cspec
|
| PP1 | Not assessed | Not assessed: no affected relatives, co-segregation observations, or countable meioses are available for the variant. |
cspec
|
| PP2 | N/A | Not applicable: PP2 requires a missense variant, whereas NM_000314.8:c.786del is a frameshift. |
cspec
pvs1_variant_assessment
|
| PP3 | N/A | Not applicable: PP3 covers synonymous/intronic splicing-impact predictions or missense REVEL >0.7, whereas c.786del is an exonic frameshift. |
cspec
|
| PP4 | N/A | Not applicable: the PTEN VCEP incorporates phenotype specificity into PS4 Use 2 rather than allowing independent PP4 application. |
cspec
|
| PP5 | N/A | Not applicable: the PTEN VCEP explicitly recommends that PP5 not be used. |
cspec
|
| BA1 | Not met | Not met: the variant is absent from gnomAD v2.1 and v4.1, rather than exceeding the BA1 threshold of >0.00056 (0.056%). |
cspec
gnomad_v2
gnomad_v4
|
| BS1 | Not met | Not met: the variant is absent from gnomAD v2.1 and v4.1, with no filtering allele frequency in either BS1 interval beginning at 0.0000043 (0.00043%). |
cspec
gnomad_v2
gnomad_v4
|
| BS2 | Not assessed | Not assessed: gnomAD reports the variant absent and provides no homozygous observations or clinical and parental-confirmation data required by BS2. |
cspec
gnomad_v2
gnomad_v4
|
| BS3 | Not assessed | Not assessed: this frameshift has no c.786del, p.Asn262LysfsTer4, or p.N262Kfs*4 assay row in the governing mmc2.xlsx dataset. |
cspec
vcep_mmc2
PMID:29706350
|
| BS4 | Not assessed | Not assessed: no affected-family non-segregation observations or family-level segregation analysis is available. |
cspec
|
| BP1 | N/A | Not applicable: the PTEN VCEP explicitly designates BP1 as not applicable. |
cspec
|
| BP2 | Not assessed | Not assessed: no qualifying trans observation or at least three cis/phase-unknown observations with different pathogenic PTEN variants are documented. |
cspec
|
| BP3 | N/A | Not applicable: the PTEN VCEP explicitly designates BP3 as not applicable for this interpretation framework. |
cspec
|
| BP4 | N/A | Not applicable: BP4 covers synonymous/intronic no-splicing predictions or missense REVEL <0.5, while c.786del is an exonic frameshift. |
cspec
|
| BP5 | Not assessed | Not assessed: no two cases with a highly penetrant alternate diagnosis and documented non-overlapping PTEN history are available for BP5. |
cspec
|
| BP6 | N/A | Not applicable: the PTEN VCEP explicitly recommends that BP6 not be used. |
cspec
|
| BP7 | N/A | Not applicable: BP7 requires a synonymous or intronic variant at or beyond +7/-21, whereas c.786del is an exonic frameshift. |
cspec
|
Disclaimer:
The content and results provided by LYFE Sciences are for research and educational purposes only and must not be used as a substitute for professional medical judgment, diagnosis, or treatment. Always consult a qualified healthcare professional before making any clinical decisions.